Recall
FDAHealthJune 30, 2025

Breckenridge Pharmaceutical, Inc. — Duloxetine Delayed-Release Capsules, USP, 40mg, 30-count bottles, Rx Only, Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Dist. by: Br

⚠️ CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit

Is this relevant to me?

Geography
Nationwide
Source agency
FDA
Category
Health
Published
June 30, 2025

U.S. Nationwide

What's affected?

Product
Duloxetine Delayed-Release Capsules, USP, 40mg, 30-count bottles, Rx Only, Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Dist. by: Breckenridge Pharmaceuticals, Inc., Berkeley Heights, NJ 07922. NDC 51991-750-33.
Lot code
230199

Additional details

Lot # 230199, Exp. Date 01/31/2026

What should I do?

Recommended action

Class II recall. Voluntary: Firm initiated Quantity affected: 12,242 30-count bottles.

View original FDA notice →

Get Health recall alerts

Delivered to your inbox. Free. No account required.